



Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis

EDUARDO ROCHA,*^o MIGUEL ANGEL MARTINEZ-GONZÁLEZ,# RAMÓN MONTES,^o CARLOS PANIZO*

*Hematology Service, University Clinic of Navarra, Pamplona; ^oHemostasis and Thrombosis Research Unit, School of Medicine, University of Navarra, Pamplona; #Preventive Medicine, School of Medicine, University of Navarra, Pamplona, Spain

ABSTRACT

Background and Objectives. We compared the efficacy and safety of low molecular weight heparins (LMWH) and unfractionated heparin (UFH) in the treatment of deep venous thrombosis (DVT). A comparison between two daily subcutaneous injections of LMWH against a single injection was also performed.

Design and Methods. The study was performed by a meta-analysis. Clot improvement in venography, recurrency, total mortality and major hemorrhages were assessed in 4,472 patients with DVT from 21 studies treated with subcutaneous LMWH or UFH.

Results. An improvement in clot reduction (odds ratio 0.73, 95% confidence interval 0.59 to 0.90, $p = 0.004$), a decrease in total mortality (0.68, 0.50 to 0.91, $p = 0.012$) and a lower incidence of hemorrhage (0.65, 0.43 to 0.98, $p = 0.047$) were observed in LMWH treated patients. There were no differences in recurrences (0.78, 0.59 to 1.04, $p = 0.10$). A single dose of LMWH was better than two in reducing major bleeding ($\chi^2 = 4.99$, $p = 0.025$); however, the two dose regimen was more effective in clot reduction ($\chi^2 = 8.56$, $p = 0.004$).

Interpretation and Conclusions. LMWH is superior to UFH in terms of safety and efficacy. A single daily dose of LMWH dose is a suitable therapeutic regimen and could facilitate the outpatient treatment of venous thromboembolism.

©2000, Ferrata Storti Foundation

Key words: LMWH; UFH; deep venous thrombosis; meta-analysis

Deep vein thrombosis (DVT) is a common complication in patients suffering from a wide variety of processes such as malignancy, spinal injuries, advanced age, and hypercoagulability syndromes as well as in patients subjected to major orthopedic or general surgery¹⁻³ with an incidence as high as 50% in patient groups not under thromboprophylaxis treatment.⁴ Although in many cases DVT resolves without sequelae, in some cases

it can lead to valvular damage and chronic venous insufficiency in subsequent years and in rare cases to an immediate threat to life from pulmonary embolism (PE) due to displacement of the thrombus.⁵ So, nowadays DVT and PE are considered as the expression of one and the same disease, termed venous thromboembolism (VTE).

Although anticoagulant therapy is the treatment of choice for most patients with VTE, the establishment of a treatment strategy is difficult because the optimum use of this treatment remains to be defined. In this setting, many regimes have been tested over the last decades including the use of oral anticoagulants, antithrombotic drugs, unfractionated heparin (UFH) and aspirin.

In recent years low molecular weight heparins (LMWH) have become available as alternatives to oral anticoagulants and unfractionated heparin for the treatment of VTE. LMWH are derived by controlled chemical or enzymatic depolymerization of standard UFH that yield chains with a mean molecular weight of about 5,000.⁶ These heparin molecules with a lower molecular weight inhibit activated coagulation factor Xa more efficiently than they inhibit thrombin because the length of the LMWH does not allow binding to both thrombin and antithrombin III. LMWH have several advantages over UFH based on their high bioavailability and more consistent anticoagulant effect at therapeutic doses, thus enabling them to be administered in fixed doses as a twice or single daily injection without the need for laboratory monitoring.^{7,8} Furthermore, for an equivalent antithrombotic effect, LMWH are thought to be less likely to cause hemorrhage with a reduced risk of bleeding, especially in surgical patients during the perioperative period.⁹

Some randomized clinical trials have been reported which compare LMWH with UFH in the treatment of DVT showing that LMWH can significantly decrease the risk of recurrence and mortality with minor risk of hemorrhagic events.^{10,11} However, most of the published works showed no statistically significant differences. Assuming an α risk of 0.05 and an expected incidence of events similar to the average of published trials, the number of patients needed in a single trial in order to achieve a statistical power of 80% would be approximately as follows: 2,350 patients for comparing the risk of clot impairment, 4,620 for total mortality, 8,520 for major bleeding and 11,500 for recurrences. The magnitude of these figures has

Correspondence: E. Rocha, M.D., Hematology Service, University Clinic of Navarra, Avenida Pio XII s/n, P.O. 4209, Pamplona, Spain.
Phone: international +34-948-296397 – Fax: international +34-948-296500 – E-mail: erocha@unav.es

Table 1. Summary of individual trial designs.

| Study | Sample size (LMWH/UFH) | LMWH used | Route of administration | |
|---|---------------------------|--------------|----------------------------|------|
| | | | LMWH | UFH |
| Bratt <i>et al.</i> , 1985 ²⁴ | 25/29 | Dalteparin | i.v. (sdd) | i.v. |
| Holm <i>et al.</i> , 1986 ²⁵ | 29/27 | Dalteparin | s.c. (tdd) | s.c. |
| Faivre <i>et al.</i> , 1988 ²⁶ | 33/37 | CY 222 | s.c. (tdd) | s.c. |
| Notarbartolo <i>et al.</i> , 1988 ²⁷ | 60/30 | OP 2123 | s.c. (sdd) | s.c. |
| Zanghi <i>et al.</i> , 1988 ²⁸ | 40/40 | OP 2123 | s.c. (sdd) | s.c. |
| Albada <i>et al.</i> , 1989 ²⁹ | 96/98 | Dalteparin | i.v. (sdd) | i.v. |
| Etude Mult. FranVaise, 1989 ³⁰ | 33/33 | Dalteparin | s.c. (tdd) | i.v. |
| Bratt <i>et al.</i> , 1990 ³¹ | 60/60 | Dalteparin | s.c. (tdd) | i.v. |
| Harenberg <i>et al.</i> , 1990 ³² | 24/26 | Certoparin | s.c. (tdd) | i.v. |
| Duroux, 1991 ³³ | 85/81 | Nadroparin | s.c. (tdd) | i.v. |
| Prandoni <i>et al.</i> , 1992 ³⁴ | 85/85 | Nadroparin | s.c. (tdd) | i.v. |
| Lopaciuk <i>et al.</i> , 1992 ³⁵ | 74/72 | Nadroparin | s.c. (tdd) | s.c. |
| Hull <i>et al.</i> , 1992 ¹¹ | 213/219 | Logiparin | s.c. (sdd) | i.v. |
| Simonneau <i>et al.</i> , 1993 ¹⁰ | 67/67 | Enoxaparin | s.c. (tdd) | i.v. |
| Tedoldi <i>et al.</i> , 1993 ³⁶ | 20/20 | OP 2123 | s.c. (sdd) | s.c. |
| Lindmarker <i>et al.</i> , 1994 ³⁷ | 101/103 | Dalteparin | s.c. (sdd) | i.v. |
| Luomanmaki <i>et al.</i> , 1996 ³⁸ | 110/116 | Dalteparin | s.c. (sdd) | i.v. |
| Fiessinger <i>et al.</i> , 1996 ³⁹ | 120/133 | Dalteparin | s.c. (sdd) | i.v. |
| Levine <i>et al.</i> , 1996 ⁴⁰ | 247/253 | Enoxaparin | s.c. (tdd) | i.v. |
| Koopman <i>et al.</i> , 1996 ⁴¹ | 202/198 | Nadroparin | s.c. (tdd) | i.v. |
| Columbus Investigators, 1997 ⁴² | 510/511 | Reviparin | s.c. (tdd) | i.v. |

LMWH: low molecular weight heparin; UFH: unfractionated heparin; i.v.: intravenous; s.c.: subcutaneous; sdd: single dose/day; tdd: two doses/day.

encouraged some researchers to perform meta-analyses in order to achieve definitive conclusions.¹²⁻¹⁶ Unfortunately, these meta-analyses have not yielded homogeneous results. This could partially be explained by the relatively small number of patients included in these studies (Table 1).

The present study was designed to assess the effectiveness and safety of UFH and LMWH in the treatment of VTE by means of a meta-analysis, taking into account the most recent studies, which were not included in any previous compilatory study, thus enhancing its analytic power. Furthermore, treatment with two daily subcutaneous injections of LMWH was compared to a single injection with regard to immediate and long term efficacy and side effects.

Design and Methods

Data collection

We performed a MEDLINE search of the literature between January 1985 and June 1999 with no restriction on the language of the paper using the following combined key words: low molecular weight heparin (LMWH) and thromboembolic disease; LMWH and deep vein thrombosis; LMWH and treatment; LMWH and clinical trial*; LMWH and meta-analysis; LMWH and review. A search in the *Excerpta Medica*, in abstracts books of meetings of the *International Society of Thrombosis and Hemostasis* and in the

Table 2. Summary of individual trial results.

| Study | Phlebography | | | | Recurrent event | | Total mortality | | Major bleeding | |
|---|-------------------|-------------------|------------------|------------------|--------------------|---------------------|-------------------|--------------------|-------------------|-------------------|
| | Clot reduction | | Clot extension | | LMWH E/Pts | UFH E/Pts | LMWH E/Pts | UFH E/Pts | LMWH E/Pts | UFH E/Pts |
| | LMWH E/Pts | UFH E/Pts | LMWH E/Pts | UFH E/Pts | | | | | | |
| Bratt <i>et al.</i> , 1985 ²⁴ | 16/25 | 14/29 | 0/25 | 3/29 | 0/25 | 0/29 | 0/25 | 0/29 | 2/13 | 0/14 |
| Holm <i>et al.</i> , 1986 ²⁵ | 10/25 | 12/25 | 1/25 | 2/25 | 1/29 | 0/27 | 0/29 | 0/27 | 0/27 | 0/28 |
| Faivre <i>et al.</i> , 1988 ²⁶ | 19/30 | 19/29 | 0/30 | 2/29 | 1/33 | 1/37 | 0/33 | 1/37 | 0/33 | 0/35 |
| Notarbartolo <i>et al.</i> , 1988 ²⁷ | - | - | - | 0/60 | 0/30 | 0/60 | 0/30 | 0/60 | 3/30 | - |
| Zanghi <i>et al.</i> , 1988 ²⁸ | - | - | - | - | 0/40 | 0/40 | 0/40 | 0/40 | 0/40 | 0/40 |
| Albada <i>et al.</i> , 1989 ²⁹ | - | - | - | - | 0/96 | 1/98 | 0/96 | 2/98 | 10/96 | 13/98 |
| Etude Mult. FranVaise, 1989 ³⁰ | - | - | 1/33 | 2/33 | 0/33 | 0/33 | 0/33 | 0/33 | 0/33 | 0/33 |
| Bratt <i>et al.</i> , 1990 ³¹ | 34/45 | 30/49 | 2/45 | 3/9 | 4/60 | 6/60 | 0/60 | 0/60 | 0/55 | 2/55 |
| Harenberg <i>et al.</i> , 1990 ³² | 13/15 | 10/13 | 1/15 | 0/13 | 2/24 | 2/26 | - | - | 2/24 | 1/26 |
| Duroux, 1991 ³³ | 54/77 | 44/71 | 5/77 | 5/71 | 1/85 | 2/81 | 3/78 | 3/73 | 2/85 | 4/81 |
| Prandoni <i>et al.</i> , 1992 ³⁴ | 50/83 | 36/85 | 5/83 | 14/85 | 6/85 | 12/85 | 5/85 | 9/85 | 1/85 | 3/85 |
| Lopaciuk <i>et al.</i> , 1992 ³⁵ | 45/68 | 32/68 | 10/68 | 12/68 | 0/74 | 3/72 | 0/74 | 1/72 | 0/74 | 1/72 |
| Hull <i>et al.</i> , 1992 ¹¹ | - | - | - | - | 6/213 | 15/219 | 10/213 | 21/219 | 1/213 | 11/219 |
| Simonneau <i>et al.</i> , 1993 ¹⁰ | 35/60 | 18/57 | 1/60 | 5/57 | 1/67 | 7/67 | 3/67 | 2/67 | 0/67 | 0/67 |
| Tedoldi <i>et al.</i> , 1993 ³⁶ | - | - | - | - | 0/20 | 1/20 | 0/20 | 0/20 | 0/20 | 0/20 |
| Lindmarker <i>et al.</i> , 1994 ³⁷ | 55/91 | 56/89 | 5/91 | 7/89 | 5/101 | 3/103 | 2/101 | 3/103 | 0/101 | 0/103 |
| Luomanmaki <i>et al.</i> , 1996 ³⁸ | 47/92 | 61/98 | 11/92 | 7/98 | 5/110 | 2/116 | - | - | 0/110 | 1/116 |
| Fiessinger <i>et al.</i> , 1996 ³⁹ | 65/96 | 62/103 | 8/96 | 12/103 | 6/111 | 3/120 | 2/111 | 4/120 | 0/120 | 2/133 |
| Levine <i>et al.</i> , 1996 ⁴⁰ | - | - | - | - | 13/247 | 17/253 | 11/247 | 19/253 | 5/247 | 3/253 |
| Koopman <i>et al.</i> , 1996 ⁴¹ | - | - | - | - | 14/202 | 17/198 | 4/202 | 7/198 | 1/202 | 4/198 |
| Columbus Investigators, 1997 ⁴² | - | - | - | - | 27/510 | 25/511 | 36/510 | 39/511 | 16/510 | 12/511 |
| Total events/pts, (%) | 443/707 (62.6) | 394/716 (55.0) | 50/740 (6.75) | 74/749 (9.87) | 93/2,225 (4.13) | 117/2,225 (5.25) | 76/2084 (3.64) | 111/2075 (5.34) | 40/2215 (1.80) | 60/2217 (2.70) |

LMWH: low molecular weight heparin; UFH: unfractionated heparin; E/pts: events/patients.

references lists of review and trials papers was also performed to avoid omission of papers that might not have been included in the MEDLINE database. We excluded non-randomized trials, and we also excluded those which were duplicate reports of data previously published.

Information was extracted from studies to assess the following issues:

- proportion of patients with any degree of impairment in the venogram, if pre- and post-treatment evaluations (by phlebography) were done and the assessment was masked with respect to treatment assignment;
- number of patients in each group developing recurrent thromboembolic events (symptomatic recurrent DVT or PE) during the trial period, if reliable diagnostic criteria were used for recurrent thromboembolism, if active follow-up was done prospectively at each center, and if the assessment was masked to treatment assignment. The diagnosis of DVT was accepted if one of the following criteria was met:
 - A) a new constant intraluminal filling defect not present on the last available venogram; or
 - B) if the venogram was not diagnostic, either an ultrasound result that had been normal before the suspected episode.¹⁷
 A diagnosis of PE was considered valid if one of the following criteria was met:
 - A) a segmental defect on the perfusion lung scan.
 - B) positive pulmonary angiography or
 - C) PE at autopsy;
- total mortality at the end of follow-up was collected from each report, if any monitoring system for active follow-up was prospectively performed by the researchers;
- the number of patients who presented major hemorrhages during the treatment was also included as an end-point to assess safety. Hemorrhages were considered major if they were fatal, or if any trans-

fusion was needed or they led to the interruption of treatment. In addition all bleeding inside the brain or into the peritoneum was also considered as a major event. All other hemorrhages were considered as minor and were not included as end-points.

Statistical methods

The risks of an impairment in phlebography, suffering recurrent thromboembolic events, death from any cause, and major hemorrhages in patients treated with LMWH and patients treated with UFH were compared by calculation of the odds ratio (OR) for each study. These ORs were pooled across studies using the Mantel-Haenszel method to estimate a common OR as an estimator of relative risk (RR). Then 95% confidence intervals (CI) were computed for the common RR using the Mantel-Haenszel method.^{18,19} In addition, the analysis was repeated using a random effect model according to Der Simonian and Laird.²⁰ ORs were also calculated with the same methodology to compare the risk of an impairment in phlebography, developing recurrent thromboembolic events, major hemorrhages and death stratifying the studies into two groups: those which used two doses of LMWH and those which used a single dose; the comparison group was UFH for both strata. The Schlesselman chi squared test was used to compare the ORs between both strata.²¹

We also estimated the number of patients needed to be treated using the incidence of events in the UFH group as the reference and applying the ORs provided by the meta-analyses.^{22,23}

Results

Comparison between LMWH and UFH

Overall 21 randomized studies^{10,11,24-42} comparing the efficacy of LMWH with that of UFH in a total of 4,472 patients were identified. In 15 trials the UFH was given intravenously (i.v.); subcutaneous (s.c.) injection was used in the remaining 6 studies. The patients in the LMWH groups received dalteparin in 8 trials [2 i.v., 3 s.c. at a single dose/day (sdd), 3 s.c. at two doses/day (tdd)], nadroparin in 4 trials (s.c., tdd), OP 2,123 in 3 trials (s.c., sdd), enoxaparin in 2 trials (s.c., tdd), CY 222 (s.c., tdd), certoparin (s.c., tdd), logiparin (s.c., sdd) and reviparin (s.c., tdd) in one trial. Each trial's design and results are summarized in Tables 1 and 2, respectively. In addition, pooled results of main end-points are given as unadjusted incidences and in terms of odds reduction as well.

Clot reduction in venography. In 13 studies (diagnosis confirmed by phlebography), the unadjusted overall improvement in venography was 55% (394 out of 716 patients) in the UFH group compared with 62.7% (443 out of 707 patients) in the LMWH group. An impairment was assessed in 9.9% of the UFH-treated patients compared with 6.7% in the LMWH group (Figure 1). The results from four of the studies^{11,33-35} showed a significant improvement in clot reduction in favor of LMWH and the results from the meta-analysis (fixed effects model) for this end-point showed that LMWH is significantly more efficient than UFH in terms of reducing thrombus extension [27% reduction, OR




Figure 1. Crude overall incidence of major end-points assessed in the meta-analysis. Number of events/total patient numbers given in parentheses for each end-point. LMWH: low molecular weight heparin; UFH: unfractionated heparin.




Figure 2. Results from meta-analysis (fixed effects model, Mantel-Haenszel method) for efficacy of treatment evaluated analyzing clot reduction in venography. Results for each trial are given; global results shown at bottom. Odds ratio <1 indicates that low molecular weight heparins performed better than unfractionated heparin, and >1 that unfractionated heparin performed better than low molecular weight heparins. Horizontal lines represent 95% confidence intervals. LMWH: low molecular weight heparin; UFH: unfractionated heparin; OR: odds ratio; CI: confidence interval.




Figure 3. Results from meta-analysis (fixed effects model) for incidence of recurrent thromboembolic events. Results for each trial are given; global results shown at bottom. Odds ratio <1 indicates that low molecular weight heparins did better than unfractionated heparin, and >1 that unfractionated heparin did better than low molecular weight heparins. Horizontal lines represent 95% confidence intervals. LMWH: low molecular weight heparin; UFH: unfractionated heparin; OR: odds ratio; CI: confidence interval.

0.73; 95% CI, 0.59 to 0.90; $p = 0.004$ (Figure 2)]. The random effects model showed very similar results. The number of patients needed to switch from UFH to LMWH in order to achieve improvement in one venography would be 13 (95% CI: 8-40).

Incidence of recurrent thromboembolism. The unadjusted overall incidence rates for recurrent thromboembolic events were 5.2% (117 out of 2,225 patients) in the UFH group, and 4.1% (92 out of 2,225 patients) in the LMWH group (Figure 1). When taken separately, only one of the studies¹¹ showed a statistically significant difference between both treatments. The results from the meta-analysis (Mantel-Haenszel




Figure 4. Results from meta-analysis (fixed effects model) for total mortality. Results for each trial are given; global results shown at bottom. Odds ratio <1 indicates that low molecular weight heparins did better than unfractionated heparin, and >1 that unfractionated heparin did better than low molecular weight heparins. Horizontal lines represent 95% confidence intervals. LMWH: low molecular weight heparin; UFH: unfractionated heparin; OR: odds ratio; CI: confidence interval.




Figure 5. Results from meta-analysis (fixed effects model) for safety of treatments evaluated by analyzing the incidence of major hemorrhagic events. Results for each trial given; global results shown at bottom. Odds ratio <1 indicates that low molecular weight heparins did better than unfractionated heparin, and >1 that unfractionated heparin did better than low molecular weight heparins. Horizontal lines represent 95% confidence intervals. LMWH: low molecular weight heparin; UFH: unfractionated heparin; OR: odds ratio; CI: confidence interval.

method) showed a near to significant statistical association with a 22% reduction in the recurrence of thromboembolism in favor of the LMWH group [OR 0.78; 95% CI, 0.59 to 1.04; $p = 0.103$ (Figure 3)]. Results with the Der Simonian and Laird method were again very similar (OR = 0.814; 95% CI, 0.61 to 1.08).

Total mortality. The unadjusted overall total mortality was higher in the UFH patients (111 out of 2,075, 5.3%) than in the LMWH group (76 out of 2,084, 3.6%) (Figure 1). When taken separately, only one of the studies¹⁰ showed statistically significant differences between both treatments. However, the

results from the meta-analysis showed a significant 33% reduction in the total mortality rate in favor of the LMWH group [OR 0.68; 95% CI, 0.50 to 0.91; $p = 0.012$ (Figure 4)].

Safety and hemorrhagic events. The unadjusted overall incidence of major bleeding was higher in the patients receiving UFH (60 out of 2,217, 2.7%) than in the patients assigned to LMWH (40 out of 2,215, 1.8%) (Figure 1). Only one of the individual studies¹⁰ showed significant differences between both treatments. However, the fixed-effects meta-analysis again showed that the risk of major hemorrhage decreased significantly in the LMWH group [35% reduction, OR 0.65; 95% CI, 0.43 to 0.98; $p = 0.047$ (Figure 5)]. This was also true for the random-effects model. The number of patients needed to switch from UFH to LMWH in order to prevent one episode of severe bleeding would be 106 (95% CI: 55-1,294).

Comparison between LMWH administered as two doses and LMWH administered in a single dose

Table 3 summarizes the results obtained when we calculated the ORs comparing LMWH and UFH separately in two strata depending on whether one or two doses of LMWH were used. The Schlesselman chi squared test for comparisons between ORs was also computed to establish the comparison between both patterns of administering LMWH and UFH. The two doses per day route exhibited a lower OR when compared with UFH and therefore seemed to be more effective than the single dose in terms of preventing thrombus extension ($\chi^2 = 8.56$, $p = 0.004$). In fact, LMWH in a single dose was not significantly more effective than UFH in reducing the clot size as the 95% CI for the OR ranged from 0.77 to 1.51 whereas it ranged from 0.42 to 0.74 in favor of LMWH in two doses when this pattern was compared with UFH. However, the administration of LMWH in a single dose was more effective than the two dose regime in reducing the risk of major bleeding ($\chi^2 = 4.99$, $p = 0.025$). In this case two doses of LMWH per day was not able to reduce the risk of major hemorrhages with respect to UFH (95% CI, 0.47 to 1.32) whereas administered as a single dose, LMWH was clearly safer than UFH (95% CI, 0.01 to 0.54). When analyzing the recurrency of thromboembolic events, there were no significant differences between both patterns of administration of LMWH or between either of them taken separately with respect to UFH, although LMWH given as two doses was almost significantly more effective than UFH (95% CI, 0.54 to 1.02). Finally, there were no differences between the two ways of administering LMWH in terms of total mortality. However, whereas a single dose of LMWH was significantly better than UFH in terms of total mortality (95% CI, 0.26 to 0.96), LMWH in two doses, although still better than UFH, was not so to a degree to reach statistical significance (95% CI, 0.53 to 1.04).

Discussion

Heparin has been the gold standard for the treatment and prophylaxis of venous thrombosis for the past fifty years.^{43,44} During the eighties LMWH under-

Table 3. Separate comparisons between LMWH and UFH depending on the number of doses of LMWH administered.

| | LMWH vs UFH | | χ^2 * | p |
|-----------------|------------------------------|--------------------------------|------------|-------|
| | Two doses [O.R. (95% CI)] | Single dose [O.R. (95% CI)] | | |
| Clot reduction | 0.56 (0.42-0.74) | 1.08 (0.77-1.51) | 8.56 | 0.004 |
| Recurrence | 0.74 (0.54-1.02) | 1.00 (0.55-1.80) | 0.74 | 0.390 |
| Total mortality | 0.74 (0.53-1.04) | 0.50 (0.26-0.96) | 1.08 | 0.300 |
| Major bleeding | 0.79 (0.47-1.32) | 0.07 (0.01-0.54) | 4.99 | 0.025 |

*Schlesselman chi-squared test for the comparison between ORs. LMWH: low molecular weight heparin; UFH: unfractionated heparin; OR: odds ratio; CI: confidence interval.

went extensive evaluation in clinical trials, mainly in those evaluating the prevention of VTE in high-risk patients.^{7,45-49} The high effectiveness of LMWH when compared with UFH in the prevention of venous thrombosis in patients undergoing major surgery, in patients with spinal injury, and in patients with stroke shown in these randomized studies led physicians to modify the thromboprophylactic regimen in these patients. In the last decade studies on LMWH have focused on the comparison between these agents and UFH in the treatment of established VTE. There is currently accumulating evidence that these new anticoagulants are also safe and effective in the treatment of acute DVT.^{7,44,48,50,51}

In this setting, we searched for and reviewed all randomized trials that compared therapy with UFH versus a LMWH in patients suffering from VTE diagnosed by clinical examination or other objective and valid diagnostic tests. Finally, a total of 4,472 patients were analyzed, thus including the highest number of patients reported so far which substantially increases the statistical power of the comparisons with respect to previous meta-analyses.

The results of this meta-analysis confirm previous findings and indicate that LMWH preparations seem to be more effective and safer than UFH for the treatment of DVT.¹²⁻¹⁶ Some discordances between meta-analyses and subsequent large-scale randomized trials have been used to highlight the caution that must be kept in mind when interpreting a meta-analysis.^{52,53} These caveats are always needed, and are relevant to our study, too. Nevertheless, meta-analyses have substantial advantages, because they can give the best available answer in each moment, can be useful to estimate sample size for a definitive trial and may provide the most reliable treatment recommendation in the situation of conflicting results from some of the trials or in the absence of definitive trials.⁵⁴

Although only a few of the individual studies analyzed showed a statistically significant improvement in clot reduction in favor of LMWH when compared with UFH,^{11,33-35} our meta-analysis shows that treatment with LMWH can be more effective in reducing thrombus size. Because thrombus extension may be related to morbidity and mortality in these patients, one of the short-term objectives for the treatment of VTE is to prevent the extension of thrombus and thus to avoid its sequelae, mainly post-phlebotic syn-

drome and thrombus recurrence. We can also speculate about the relationship between thrombus extension and an increased embolic risk as Pollak⁵⁵ previously suggested.

When efficacy of LMWH was assessed by comparing the appearance of recurrent VTE we were unable to find statistically significant differences between treatment with LMWH and UFH. Although an approximately 50% reduction in the relative risk of recurrent venous thrombosis has been reported in the meta-analysis of early trials of LMWH as compared with UFH in the treatment of DVT,^{12,14,15} our findings are inconsistent with a reduction of this magnitude and more similar to results of other previous studies.^{13,16} However, the difference seen for this end-point was also in favor of the LMWH in our study. Possibly in the future new and more potent meta-analyses (including new comparative works and thus a higher number of patients) will reach a statistically significant difference in favor of LMWH.

When taken separately, only the study by Hull *et al.*¹⁰ showed a statistically significant difference in mortality between the two treatments. However, the significant reduction in mortality in the LMWH group shown in our study is consistent with the results of a similar meta-analysis reported previously.^{14,15} Although mortality might be a pertinent end-point for evaluating the efficacy of an antithrombotic drug, death in patients with VTE usually occurs after the initial treatment period. Moreover, very few deaths of those reported in the studies analyzed are due to fatal PE, which supports the hypothesis proposed by Douketis *et al.*⁵⁶ that fatal PE is a rare event in patients who have correctly followed anticoagulant treatment. So, mortality within the first months seems to be related to underlying diseases. In this setting, although not adding new data to this issue, we agree with other authors who suggest that malignant disease may explain many of the deaths in the studies, as cancer is an important risk factor for VTE and many patients in the trials analyzed had an oncologic disease.^{10,34} The cause of the reduced mortality in cancer patients treated with LMWH is therefore a both intriguing and difficult finding to explain. We can hypothesize that anti-tumor growth factor activity or suppression of angiogenesis could be induced more effectively by LMWH than by UFH.^{57,58} Nevertheless, further confirmation in prospective randomized trials is required.

Severe bleeding is an important concern when studying the efficacy and safety of an anticoagulant therapy. Although, of all the studies analyzed, only one study¹⁰ showed a significant difference in the rates of major bleeding between treatment groups, when pooled together by means of the meta-analysis, the studies showed that the use of LMWH produced a statistically significant lower incidence of major bleeding. It is important to note that this reduction in the rate of major hemorrhage when the treatment was with LMWH was not at the cost of decreasing the efficacy of the anticoagulation regimen.

Recent studies have demonstrated the possibility and the advantages of outpatient administration of LMWH.^{40,41,59,60} However, little is known about the

results of the comparison between the patients given LMWH in two doses or as a single dose. With regard to this point, although LMWH given as two doses was better in decreasing phlebographic changes, treatment as a single dose was equally effective in terms of preventing recurrence and total mortality, and achieving a statistically significant reduction in major hemorrhage. Thus, our results further substantiate the concept that the effects of a single dose of LMWH could be as efficient as and safer than the two-dose regimen, which would facilitate the outpatient treatment of VTE proposed by other authors.^{40,41}

We, therefore, conclude that LMWH is superior in terms of safety and efficacy when compared with UFH in unselected patients with DVT. Moreover, LMWH regimens have several practical advantages. They are more comfortable for patients, less time consuming for nurses and produce less work for laboratories. In addition, the fact that the single dose of LMWH is a suitable therapeutic regimen would facilitate the outpatient treatment of VTE.

Contributions and Acknowledgments

ER was the principal clinician involved and responsible for the study design and collection of the data. MAGM performed the statistical analyses. RM and CP contributed to the analysis of the data, and wrote the manuscript. All authors approved the final version of this manuscript.

Disclosures

Conflict of interest: none.

Redundant publications: no substantial overlapping with previous papers.

Manuscript processing

Manuscript received May 3, 2000; accepted June 20, 2000.

Potential implications for clinical practice

- ♦ The results of this meta-analysis indicate that LMWH preparations seem to be more effective and safer than UFH for the treatment of DVT. Our results further substantiate the concept that the effects of a single dose of LMWH could be as efficient and safer than the two-doses regimen, which would facilitate the outpatient treatment of venous thromboembolism.

References

1. Wells PS, Ginsberg JS, Anderson DR, et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. *Ann Intern Med* 1998; 129:997-1005.
2. Perrier A, Desmarais S, Miron MJ, et al. Non-invasive diagnosis of venous thromboembolism in outpatients. *Lancet* 1999; 353:190-5.
3. Wells PS, Hirsh J, Anderson DR, et al. A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. *J Intern Med* 1998; 243:15-23.
4. Agnelli G, Sonaglia F. Prevention of venous thromboembolism in high risk patients. *Haematologica*

- 1997; 82:496-502.
5. Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalised medical patients. *J Clin Pathol* 1997; 50:609-10.
 6. Weitz JI. Low-molecular-weight heparins. *N Engl J Med* 1997; 337:688-98.
 7. Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. *Thromb Res* 1985; 39:631-6.
 8. Hull RD, Pineo GF, Valentine KA. Treatment and prevention of venous thromboembolism. *Semin Thromb Hemost* 1998; 24:21-31.
 9. Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. *Blood* 1982; 59:1239-45.
 10. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. *Arch Intern Med* 1993; 153:1541-6.
 11. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. *N Engl J Med* 1992; 326:975-82.
 12. Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AW. Low molecular weight heparin: a critical analysis of clinical trials. *Pharmacol Rev* 1994; 46:89-109.
 13. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. *Br Med J* 1994; 309:299-304.
 14. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. *Arch Intern Med* 1995; 155:601-7.
 15. Hirsh J, Siragusa S, Cosmi B, Ginsberg JS. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. *Thromb Haemost* 1995; 74:360-3.
 16. Turkstra F, Koopman MM, Buller HR. The treatment of deep vein thrombosis and pulmonary embolism. *Thromb Haemost* 1997; 78:489-96.
 17. Buller HR, Lensing AW, Hirsh J, ten-Cate JW. Deep vein thrombosis: new non-invasive diagnostic tests. *Thromb Haemost* 1991; 66:133-7.
 18. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 1959; 22:719-98.
 19. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. *Stat Med* 1987; 6:245-54.
 20. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; 7:177-88.
 21. Schlesselman JJ. In: Case-control studies. New York: Oxford University Press; 1982.
 22. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. *Br Med J* 1995; 310:452-4.
 23. Altman DG. Confidence intervals for the number needed to treat. *Br Med J* 1998; 317:1309-12.
 24. Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep vein thrombosis. *Thromb Haemost* 1985; 54:813-7.
 25. Holm HA, Ly B, Handeland GF, Abildgaard U, et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. *Haemostasis* 1986; 16 (Suppl 2):30-7.
 26. Favier R, Neuhart Y, Kieffer Y, et al. A new treatment of deep venous thrombosis: low molecular weight heparin fractions. Randomized study. *Presse Med* 1988; 17:197-200.
 27. Notarbartolo A, Salanitri G, Davi G, Averna M, Barbagallo C, Catalano I. Low molecular weight heparin in the short and long-term treatment of deep vein thrombosis in diabetic subjects. *Med Prax* 1988; 9:393-405.
 28. Zanghi M, Morici V, Costanzo M, Astuto L, Salanitri G. Deep vein thrombosis of the legs: new therapy by means of low molecular weight heparins. *J Intern Med* 1988; 16:474-84.
 29. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (fragmin). Results of a double-blind randomized study. *Circulation* 1989; 80:935-40.
 30. Treatment of deep venous thrombosis. Comparative study of a low molecular weight heparin in fragment (fragmin) by the subcutaneous and standard heparin by the continuous intravenous route. A multicenter study. *Rev Med Interne* 1989; 10:375-81.
 31. Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). *Thromb Haemost* 1990; 64:506-10.
 32. Harenberg J, Kallenbach B, Martin U, et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. *Thromb Res* 1990; 59:639-50.
 33. Duroux P. A Collaborative European Multicentre Study: a randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. *Thromb Haemost* 1991; 65:251-6.
 34. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. *Lancet* 1992; 339:441-5.
 35. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. *Thromb Haemost* 1992; 68:14-8.
 36. Tedoldi A, Botticella F, Maloberti MR. Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis. *Clin Trials Meta-analysis* 1993; 28:215-25.
 37. Lindmarker P, Holmstrom M, Granqvist S, Johansson H, Lockner D. Comparison of once-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. *Thromb Haemost* 1994; 72:186-90.
 38. Luomanmaki K, Granqvist S, Hallert C, et al. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. *J Intern Med* 1996; 240:85-92.
 39. Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. *Thromb Haemost* 1996; 76:195-9.
 40. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. *N Engl J Med* 1996; 334:677-81.

41. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. *N Engl J Med* 1996; 334:682-7.
42. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. *N Engl J Med* 1997; 337:657-62.
43. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. *N Engl J Med* 1988; 318:1162-73.
44. Ginsberg JS. Management of venous thromboembolism. *N Engl J Med* 1996; 335:1816-28.
45. Pineo GF, Hull RD. Prophylaxis of venous thromboembolism following orthopedic surgery: mechanical and pharmacological approaches and the need for extended prophylaxis. *Thromb Haemost* 1999; 82: 918-24.
46. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. *JAMA* 1994; 271:1780-5.
47. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. *Lancet* 1992; 340:152-6.
48. Bounameaux H, Goldhaber SZ. Uses of low-molecular-weight heparin. *Blood Rev* 1995; 9:213-9.
49. Hirsh J, Levine MN. Low molecular weight heparin. *Blood* 1992; 79:1-17.
50. Kearon C. Initial treatment of venous thromboembolism. *Thromb Haemost* 1999; 82:887-91.
51. Bates SM, Hirsh J. Treatment of venous thromboembolism. *Thromb Haemost* 1999; 82:870-7.
52. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. *N Engl J Med* 1997; 337:536-42.
53. Bailar JC 3rd. The promise and problems of meta-analysis. *N Engl J Med* 1997; 337:559-61.
54. Borzak S, Ridker PM. Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. *Ann Intern Med* 1995; 123:873-7.
55. Pollak EW. Early diagnosis of anticoagulation failure: can recurrent pulmonary embolism be prevented? *Int Surg* 1980; 65:219-22.
56. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. *JAMA* 1998; 279: 458-62.
57. Jayson GC, Gallagher JT. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. *Br J Cancer* 1997; 75:9-16.
58. Norrby K, Ostergaard P. Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. *Int J Microcirc Clin Exp* 1996; 16:8-15.
59. Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. *Arch Intern Med* 1998; 158:1809-12.
60. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. *Arch Intern Med* 1998; 158:2001-3.